They further examined the relative expression levels of MYT1 and MYT1L in human brain cancer datasets showing that MYT1L was expressed in a lower rate in oligodendroglioma, astrocytoma (grade III), and GBM compared to normal brains. Here, MYT1L is linked to brain cancer.